Cargando…

Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients

SIMPLE SUMMARY: Aberrant expression of telomere-related genes (TRGs) and telomere-shortening facilitates development of different types of cancer. Given the fact that high-risk multiple myeloma (MM) patients harbor critically shortened telomeres, we investigated the epigenetic basis of TRG-expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy Choudhury, Samrat, Ashby, Cody, Zhan, Fenghuang, van Rhee, Frits
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699806/ https://www.ncbi.nlm.nih.gov/pubmed/34944968 http://dx.doi.org/10.3390/cancers13246348

Ejemplares similares

Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
por: Roy Choudhury, Samrat, et al.
Publicado: (2023)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

P975: THREE-DIMENSIONAL TELOMERE PROFILING PREDICTS RISK OF RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Kumar, Shaji, et al.
Publicado: (2023)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling
por: Teh, Benjamin W., et al.
Publicado: (2017)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
por: Danziger, Samuel A., et al.
Publicado: (2020)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma: Erratum
Publicado: (2016)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017)

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
por: Saburi, Masuho, et al.
Publicado: (2020)

Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
por: Rifkin, Robert M., et al.
Publicado: (2019)

A simple additive staging system for newly diagnosed multiple myeloma
por: Abdallah, Nadine H., et al.
Publicado: (2022)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients
por: Mielnik, Michał, et al.
Publicado: (2023)

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
por: Biran, Noa, et al.
Publicado: (2021)

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
por: Davies, Faith E., et al.
Publicado: (2018)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

Elevation of Serum Ferritin is Associated with the Outcome of Patients with Newly Diagnosed Multiple Myeloma
por: Song, Moo-Kon, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_frkpgea5944ldgc1h51vh62cvi